Investors expect the company to underperform the broader industry, contributing to its low P/S ratio. The company's recent revenue decline could stagnate the share price if the trend continues.

North China Pharmaceutical Company.Ltd's recent share sell-off could be an opportunity. However, the company shows 1 warning sign in investment analysis, potentially not the best stock to buy.